Osteoarthritis (OA) is the most common form of arthritis, mainly characterized by cartilage destruction. Despite the increasing number of OA patients, no cure for this disease has been found to date. The therapies currently available primarily address the handling of joint pain. The failure of conventional treatments (analgesics or non-steroidal anti-inflammatory drugs) to regenerate or slow the degeneration of damaged cartilage, combined with their frequent adverse side effects, may explain the increasing use of SYSADOA (SYmptomatic Slow-Acting Drugs for Osteoarthritis) therapies such as chondroitin sulfate (CS) and glucosamine (GlcN). Although several clinical trials have examined the structure-modifying effects of these drugs[@b1][@b2][@b3][@b4][@b5][@b6], the outcomes of the treatment with a combination of glucosamine and chondroitin sulfate (Glu/CS) on knee OA progression are still under debate. The recent Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT study) suggests that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain[@b7]. In a more recent analysis by Pelletier et al., using data from participants enrolled in the progression cohort of the OAI, there was evidence of a beneficial effect of the Glu/CS at delaying knee OA structural progression: Participants who took Glu/CS had reduced loss of cartilage volume over 24 months in subregions assessed with qMRI, thus supporting a disease-modifying effect of Glu/CS that could not be identified by X-rays[@b8]. However, recent meta-analysis fuel the controversy surrounding the efficacy of these drugs in terms of pain and structure modifications, stimulating further investigations about the mechanistic effects of CS and GlcN[@b9].

The effect of combined formulations of chondroitin and glucosamine has been extensively reported in several *in vitro* studies[@b10][@b11][@b12][@b13][@b14]. *Chan* and collaborators demonstrated that, in bovine cartilage explants, the combination of CS with glucosamine hydrochloride was slightly better than glucosamine alone in inhibiting both inflammatory and catabolic intermediates. However, the effects of the combined formulation on chondrocytes extracellular matrix (ECM) metabolism remain poorly understood, and their action on factors involved in cartilage remodelling has never been investigated by proteomic tools.

Proteomics is being increasingly applied for the study of drug modes of action, side-effects and toxicity, and it is also a valuable approach for the discovery of new drug targets. In OA research, our group exhibits a good track record employing quantitative proteomics technologies for anti-OA drug screening. In 2010, we published the first pharmacoproteomic study aimed to unravel the molecular mechanisms driven by CS alone or in combination with GlcN sulfate[@b15], which was performed by a gel-based proteomic analysis of human articular chondrocytes (HACs) stimulated with IL-1β. In that work, a large number of target proteins of CS and GlcN were described, pointing out the different mechanisms of action of these drugs. Nevertheless, in most cases both molecules synergistically modified the chondrocyte proteome, showing a potent effect on oxidative stress and modulation of energy production and metabolic pathways. Furthermore, using that approach we could only evaluate the intracellular mechanisms modulated by CS and GlcN, which are the background for ulterior putative changes of ECM turnover. Once the utility of proteomics for analyzing the intracellular targets of these two drugs was proved, we decided to focus on the analysis of the subset of chondrocyte extracellular proteins that are essential for cartilage ECM synthesis and turnover processes. With this objective, a quantitative profile of the chondrocyte extracellular protein changes driven by CS both in normal and OA chondrocytes was recently obtained by the SILAC technique[@b16][@b17]. These works provided novel molecular evidences of CS properties and underlined the need of stricter regulations regarding CS quality control. Furthermore, for the first time, chondrocyte secretome emerged as an attractive starting point for the discovery of new OA drug targets (i.e. angiogenesis) and also for the identification of novel efficacy markers for monitoring different OA treatments.

In the present work, we analyze the synergic effect of glucosamine and chondroitin sulfate, addressing for the first time the study of chondrocytes secretome using a gel-free approach and employing the isobaric tags for relative and absolute quantitation (iTRAQ) methodology, in order to overcome the limitations of the classical electrophoresis-based methods (DIGE and SILAC). By these means, we have performed a shotgun proteomics experiment on OA HACs secretomes that pursued to evaluate the combined effect of CS and GlcN on cartilage ECM biology, and to better characterize their mechanism of action.

Results
=======

Secretome profiling of CS- and/or GlcN-treated HACs
---------------------------------------------------

Supernatants from OA HACs, treated with CS alone or in combination with GlcN, were collected after 48 hours of incubation for the proteomic analysis. Samples were concentrated by filtration, cleaned up by acetone precipitation and quantified. An aliquot of these samples was resolved by SDS-PAGE. As revealed by silver staining ([Supplementary Figure S1](#s1){ref-type="supplementary-material"}), HAC supernatants display a medium complexity. Nevertheless, we decided to carry out a two-dimensional approach in order to achieve the greatest number of identified proteins. A schematic workflow of this work is depicted in [Fig. 1](#f1){ref-type="fig"}. Firstly, equal amounts of proteins from the experimental conditions to be compared (treated or untreated with CS and/or GlcN) were digested with trypsin, and then the correspondent tryptic peptides were labeled with four different iTRAQ tags. The resulting labeled peptides were combined and separated using reversed phase LC prior to MS analysis for the identification and relative quantification of the corresponding proteins. Biological (n = 3) and technical (n = 2) replicates were analyzed to increase the reliability of the iTRAQ technique for relative quantitation[@b18]. A total of 186 proteins could be identified in chondrocytes secretome after combining the results from all the experiments (false discovery rate at 1%) with two or more peptides with 95% confidence and total score ≥ 2, and quantified ([Supplementary Table S1](#s1){ref-type="supplementary-material"}). As expected, many of the identified proteins were ECM components of mature cartilage or matrix regulating factors including proteases, protease inhibitors, growth factors, and anti-inflammatory agents. Furthermore, the iTRAQ labeling allowed us to identify 9 unique peptides of collagen II (COL2A1), a specific cartilage marker that was not previously detected using the MALDI-MS approach. This might be due to the improved MALDI ionization of the peptides that is triggered by the iTRAQ method, and also to the independence of this technique from newly protein synthesis rate. In fact, previous studies on chondrocytes using SILAC labeling failed to identify COL2A1[@b16][@b19][@b20], which can be attributed to the very low rate of type II collagen turnover. A higher number of COL2A1 peptides has been detected only in studies on articular cartilage (from mouse and human origin) using a different type of ionization source (electrospray)[@b21][@b22][@b23]. Considering the global effect of the pharmacological treatment in altering chondrocytes secretome profile, we found thirty-six proteins significantly modulated (*p*value ≤ 0.05) in OA treated cells when compared to untreated ones (basal condition): 32 were increased and 4 were decreased ([Table 1](#t1){ref-type="table"}). Among them, CS alone altered the expression of twenty-eight HACs secreted proteins, while GlcN alone modulated only twelve of these proteins. Data analysis resulted more informative when we compared the effect of the combined formulation with each compound separately ([Table 2](#t2){ref-type="table"}). We found 18 proteins upregulated and only one, VIM, downregulated when we analyzed GlcN alone or in combination with CS ([Table 2A](#t2){ref-type="table"}). Among them we found thrombospondin-1 (THBS1 or TSP1), a protein recently described by our group as potential new target for OA treatment[@b16]. GlcN alone is unable to alter THBS1 expression level, but when combined with CS a strong increase is observed (ratio = 3,281; *p*value = 0,0001). On the other hand, when we focused on CS alone or in combination with GlcN, only 3 proteins were found as significantly modulated: VIM and FN1 increased and TGFBI decreased ([Table 2B](#t2){ref-type="table"}).

Bioinformatic analysis of differentially expressed proteins
-----------------------------------------------------------

The STRING database was searched for protein interaction analyses in order to elucidate the effect of CS alone and in combination with GlcN. As shown in [Figure 2](#f2){ref-type="fig"}, almost all (28) of the altered proteins interact with each other to constitute a big network. These proteins are involved in three main GO biological processes characteristic of connective tissue such as cell adhesion, cartilage development, and ECM organization. Among them, proteins such as collagen VI, XII, and tenascin showed increased release to the medium following all three treatments ([Fig. 3A](#f3){ref-type="fig"}). The Pike tool was used to assign the cellular compartment of the identified proteins[@b24]. As shown in [Fig. 3B](#f3){ref-type="fig"}, 60% of them are classically annotated as secreted proteins.

Verification of the modulation of THBS1 and TGFBI in NvsOA HACs
---------------------------------------------------------------

Taking into account previous proteomics results by our group[@b16][@b20], we focused in particular on two proteins identified in this study: THBS1 and TGFBI. In our previous studies we could verify a significant modulation in the secretion of these proteins in IL1β-stimulated HACs. In the present work, Real Time-PCR assays demonstrated that THBS1 gene expression levels are decreased (ratio = 0,45; *p*value ≤ 0,05), while those of TGFBI are increased (ratio = 1,98; *p*value ≤ 0,05) in OA HACs compared to normal cells ([Fig. 4](#f4){ref-type="fig"}). GlcN alone does not alter the expression of either THBS1 or TGFBI, whereas CS alone upregulates both genes ([Table 1](#t1){ref-type="table"}). Finally, CS + GlcN upregulates THBS1 compared to untreated cells ([Table 1](#t1){ref-type="table"}) and dowregulates TGFBI compared to CS-treated cells ([Table 2B](#t2){ref-type="table"}).

Modulation of THBS1 by CS
-------------------------

In our previous studies we observed an increase of THBS1 or TSP1 (an angiogenesis inhibitor) driven by CS both in absence of IL1β stimulation, in OA chondrocytes[@b17], and also in presence of this potent inflammatory cytokine in N cells[@b16]. In this case, as shown in [Fig. 5](#f5){ref-type="fig"}, we detected a remarkable increase of thrombospondin 1 as a consequence of the cell treatment with CS alone (both at mRNA and protein level) and in combination with GlcN (only at protein level). Moreover, if we compared the effect of the combined formulation with that of GlcN alone, we observed a statistically significant increase in THBS1 protein expression level ([Table 2A](#t2){ref-type="table"}, [Fig. 5B](#f5){ref-type="fig"}).

Discussion
==========

We have performed a gel-free quantitative proteomics experiment for the analysis of secretomes (cell conditioned media) from CS and/or GlcN-treated OA HACs. This study has allowed us to generate a quantitative profile of chondrocyte extracellular protein changes driven by different CS formulations (simple and combined with GlcN). The strategy used is based on the differential labeling of peptides with iTRAQ reagents prior to their separation and analysis by multidimensional LC coupled to MS ([Fig. 1](#f1){ref-type="fig"}). A previous analog study by our group described intracellular changes driven by CS and GlcN using a classical proteomic approach by 2DE[@b15]. 2DE is a powerful proteomic profiling technique for both protein identification and quantitation; however this traditional method showed some limitations in term of reproducibility. Furthermore, the 2DE platform fails to detect proteins with extreme pH values (greatly represented in cartilage by the high density and anionic nature of proteoglycans), high or low molecular weight, proteins present in low copy numbers, and those with hydrophobic domains. In this sense, LC-MS/MS analysis overlaps these drawbacks, which are particularly important given the especial features of HACs, which synthesize and secrete a variety of highly anionic compounds (glycosaminoglycans) and a few abundant proteins (mainly collagens and proteoglycans) that hamper the performance of 2-DE-based approaches. Therefore, we recently developed an alternative method based on metabolic labeling (SILAC) for the quantitative analysis of chondrocytes proteome and secretome[@b16][@b17][@b20], and also for the analysis of human bone marrow mesenchymal stem cells proteome during chondrogenic differentiation[@b25]. In this case, the main disadvantage is the limited number of conditions that can be compared simultaneously (usually two), and also the large culture time needed to obtain the fully labeled cell populations that are necessary for quantification. For all these reasons, LC-MS techniques have begun to exercise their dominance in the OA research field. Among these strategies, the use of iTRAQ protein tags significantly reduce sample-to-sample and time-point variation[@b26], improves the ionization and subsequent analysis of peptides and finally allows the quantification of proteins in samples from different subjects, stages of disease or treatment conditions (up to 8) in a rapid and reproducible way.

The present study demonstrates the different effects of the simple and the combined administration of CS on OA HACs. CS alone increased the expression level of 24 proteins and decreased 4 ([Tab. 1](#t1){ref-type="table"}). Interestingly, the four decreased proteins are intracellular: two with a structural function (VIM, MSN), a glycolytic enzyme (PKM2), and a chaperone (HSP90B). Both vimentin and heat shock protein 90 beta are described in literature as OA-related proteins, as their protein expression levels are altered in OA chondrocytes[@b27][@b28]. Increased vimentin fragments were observed in a rat OA model[@b29] and also in human OA cartilage[@b30], and this correlates with a disrupted vimentin network. Here, we found that VIM is decreased by CS treatment ([Table 1](#t1){ref-type="table"}). Therefore, we hypothesize that CS could be effective in restoring a proper cytoskeleton network in OA-affected chondrocytes. On the other hand, a previous proteomic analysis performed by our group revealed an increase of the β subunit of the chaperone Hsp90 in diseased cells[@b28]. Many metabolic processes contributing to age-related changes in cartilage ECM are influenced by known roles of Hsp90β, such as COL2A1 and MMP-13 expression and NO synthesis[@b31][@b32]. Our result suggests that the well documented anabolic, anti-catabolic and anti-inflammatory properties of CS should be partially mediated by the Hsp90 inhibition observed in CS-treated chondrocytes[@b10][@b11][@b12][@b33][@b34]. However, further studies are needed to determine whether Hsp90β could serve as a therapeutic target of CS for reducing cartilage degradation in OA.

In OA HACs treated with GlcN alone, all of the modulated proteins were increased when compared to the untreated cells ([Tab. 1](#t1){ref-type="table"}). Generally, the increase observed is lower than the one observed with CS for the same proteins (except for ANXA5). Two proteins (CHI3L1 and PENK) were modulated only by GlcN alone or combined with CS, and one was found to be positively modulated only by GlcN alone (LDHA). Interestingly, in our first pharamacoproteomic study[@b15], all the proteins modulated by glucosamine sulfate (GS) related to energy production were decreased; while in the case of GlcN·HCl we found a slight increase (ratio = 1,888; *p*value = 0,0272) of this glycolytic enzyme. This difference could be determined by the different GlcN formulation employed, but probably also by the different cellular compartment analyzed.

Similar to the GAIT study[@b7], many clinical trials tested CS together with glucosamine[@b2][@b35][@b36]. The results suggest that both components may enhance each other\'s efficacy. This synergistic effect was also proposed by various *in vivo* and *in vitro* studies[@b10][@b11][@b12][@b13][@b37][@b38][@b39]. As reviewed in recent works[@b40][@b41][@b42], the mechanism of action of CS differs in several aspects from that of GlcN. *In vivo* and *in vitro* experiments have demonstrated that CS reaches the joint, and distributes into the cartilage and subchondral layers[@b43][@b44]. However, being a large molecule, CS does not penetrate into the cells[@b45], and so elicits its anti-inflammatory effect by engaging chondrocytes membrane receptors, e.g. CD44, TLR4, and ICAM1. In fact there is evidence that CS directly and/or indirectly modulates CD44 anti-inflammatory effects. CS engages CD44 and is internalized[@b46][@b47]. By binding to this receptor, CS could modulate transcriptional factors such as NF-κB thus blocking pro-inflammatory signaling pathways with down-regulation of target genes, such as ADAMTS, MMPs, IL-1β, and iNOS[@b48]. Campo et al. had also demonstrated that CS could act on the toll-like receptor (TLR)-4 to inhibit the inflammatory cytokines, MyD88 and tumour necrosis factor (TNF) receptor associated factor (TRAF)-6, through the inhibition of nuclear factor (NF)-kB activation[@b49]. CS maintains the integrity of the cartilage ECM by two ways: reducing the expression of MMP1, MMP3, MMP13, ADAMTS1 and ADAMTS2, hence preventing the degradation of collagen, proteoglycans and aggrecan[@b48]; engaging integrins and increasing TGF-β1 expression that fosters the synthesis of hyaluronic acid and collagen II[@b41]. In addition, CS-containing proteoglycans play important roles in growth factor signaling *in vivo*, particularly during chondrogenesis[@b50]. Due to its highly negative charge, CS is able to interact electrostatically with positively charged growth factors such as TGFβ1[@b51]. This ability to sequester growth factors should be exploited as drug delivery vehicles for controlled delivery and release, especially for repair of cartilaginous tissues[@b52]. On the other hand, GlcN penetrates into cells by means of glucose transporters (GLUTs). Once taken up by cells, exogenous GlcN is phosphorylated into GlcN-6-phosphate, which subsequently enters into the hexosamine biosynthetic pathway to generate UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is a substrate for the synthesis of proteoglycans, glycolipids, and glycoproteins but also for protein acylation through O-linked GlcNAcylation (O-GlcNAc)[@b53]. Proteins can be modified reversibly at serine or threonine residues by attachment of a GlcNAc molecule. As suggested by Scotto D\'Abusco et al. the effects of GlcN could derive, at least in part, from its capacity to O-GlcNAcylate proteins, primarily kinases (JNK, p38 and IKKα)[@b54][@b55]. In the case of chondrocytes treated with GlcN, this protein modification competes with phosphorylation by utilizing the same amino acidic sites and, as a consequence, GlcN reduces NF-κB nuclear translocation and abrogates the transcription of proteolytic and pro-inflammatory target genes. In our first pharmacoproteomic study we evaluated the potency of the use of CS in combination with GlcN[@b15]. These compounds produced different patterns of protein modification when tested alone or in combination. However, in most cases a synergistic effect was demonstrated when cells were exposed to both compounds, implying a potent effect on oxidative stress as indicated by the modulation of superoxide dismutase. Finally we can conclude that the differences in their mechanism of action could explain why the combination of CS and GlcN should be more effective than each individual drug supporting the use of the combined formulation. In the present study we focused on the subset of secreted proteins in order to identify putative novel biomarkers that would be easily detectable in the bloodstream of treated patients and therefore useful to discriminate responders and non-responders. The Venn diagram showed in [Fig. 3A](#f3){ref-type="fig"} depicts the overlap of proteins modulated in OA chondrocytes by each treatment, and is quite similar to that previously obtained in normal HACs stimulated with IL1β. In the case of CS, we observed a 62% of similarity with the combined treatment, while in the case of GlcN only a 33% was detected. A slight synergistic effect was noticed for some ECM components (ACAN, CHI3L1, COL5A1, and COL12A1). In other cases, a statistically significant modulation was seen only when CS and GlcN were employed together (COMP, FN1, and LUM).

As concluding remarks, our findings confirm in OA HACs the synergistic chondroprotective effect of chondroitin sulfate and glucosamine hydrochloride that was previously described by our group in normal cells. In fact, despite having employed in such studies different proteomic strategies based on 2DE, DIGE and SILAC, the modulation of several proteins (like VIM, PKM2, THBS1) in CS-treated chondrocytes has been observed also in this study ([Table 3](#t3){ref-type="table"}). Moreover, the iTRAQ approach exhibits the advantages for the relative quantification of HACs secreted proteins. This is especially useful to focus on cartilage ECM proteins, which have particular importance for their role in proper tissue maintenance. To our knowledge, this is the first time that COL2A1 is identified by MALDI-MS in chondrocytes secretome. If the presence of this protein into the conditioned medium represents new matrix synthesis, matrix degradation, or passive loss of components from the chondrocytes needs to be investigated. Furthermore, the subset of OA chondrocyte extracellular proteins has been successfully evaluated for the search of non-invasive OA biomarkers. In fact, the main goal of this study, in addition to focus on the evaluation of the combined formulation, is also to serve as novel source for OA biomarker discovery. Several proteins have emerged as putative candidate biomarkers and, hopefully, the negative correlation between THBS1 and TGFBI expression that we have encountered can be exploited in the next future for screening the presence of OA disease or monitoring therapeutic effectiveness in clinical samples. Especially THBS1, which is downregulated in OA chondrocytes and then upregulated after pharmacological treatment, could be a good standard for the outcome measures of clinical trials assisting data interpretation and enabling rigorous comparisons between different studies. However, further investigations on biological fluids are necessary to assess its biomarker usefulness.

Methods
=======

Cartilage procurement and processing
------------------------------------

Cartilage obtained from three OA patients (73, 78 and 84 years old) undergoing joint replacement was provided by the Tissue Bank and the Autopsy Service at CHU A Coruña for the pharmacoproteomic analysis. The study was approved by the local Ethics Committee. Articular chondrocytes were isolated from human cartilages as previously described[@b15][@b56]. Briefly, once cartilage surfaces were rinsed with saline, scalpels were used to cut parallel sections 5 mm apart, vertically from the cartilage surface onto the subchondral bone. These cartilage strips were then cut-off from the bone, and the tissue was incubated with trypsin at 37°C for 10 min. After removing trypsin solution, the cartilage slices were treated for 12--16 h with type IV clostridial collagenase in DMEM with 10% FBS in order to release cartilage cells.

Chondrocytes culture and pharmacological treatment
--------------------------------------------------

Chondrocytes were recovered and cultured in DMEM supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 1% glutamine, and 10% FBS. Cells were seeded onto 100 mm culture plates for proteomic studies or 6-well plates for total RNA extraction. The cells were incubated at 37°C in a humidified gas mixture containing 5% CO2 balanced with air. Chondrocytes were used at weeks 2--3 in primary culture, after making them quiescent by incubation in a medium containing 0.5% FBS for 24 h. Finally, cells were cultured for 48 hours in serum free medium containing chondroitin sulfate (CS) and/or glucosamine hydrochloride (GlcN or GH). Both molecules were pharmacological grade and were provided by Bioiberica S.A. (Barcelona, Spain). CS was from bovine origin, with a CS content of 99.9% and a molecular weight of 15.12 kDa. Other characteristics (viscosity, sulfation sites, etc.) have been previously detailed elsewhere[@b17][@b57]. CS and GlcN concentrations (both 200 μg/mL) were optimized for the proteomic studies in accordance with previous results by our group and literature data[@b15][@b20] where a very wide range of both glucosamine and chondroitin sulfate have been used on different cell types and tissues. These concentrations are also in accordance with those tested in the standardization step of our proteomic analysis (CS from 20 to 200 μg/ml and GlcN from 1 to 10 mM).

Processing of conditioned media for iTRAQ labeling
--------------------------------------------------

Conditioned media (CM) obtained from 3 different samples were analyzed independently. CM were collected, centrifuged and filtered using a 0.2 μm filter to ensure removal of any dead cells. Supernatant of each dish (6 mL) was concentrated to a final volume of 250 μl with Amicon ultrafiltration units (5 kDa MWCO, Millipore, Billerica, MA, USA) and then cleaned up by acetone precipitation. Protein pellets were dried in air and then resuspended in 25 μl Dissolution Buffer. Protein concentrations were determined by Bradford assay (Sigma-Aldrich, St. Louis, MO, USA). Equal amounts of chondrocyte secreted proteins (20 μg) from each condition were reduced, alkylated, and digested with trypsin. Then iTRAQ labeling was performed according to the supplier\'s instructions (ABSciex, Foster City, CA, USA). The samples were labeled as follows: controls, 114; CS, 115; GH, 116; CS + GH, 117. iTRAQ-labeled peptides were mixed and desalted using reversed phase columns (Pierce C18 Spin Columns, Thermo Fisher Scientific, Rockford, IL, USA) prior to liquid chromatography coupled to mass spectrometry (LC-MS) analysis ([Fig. 1](#f1){ref-type="fig"}).

LC-MS analysis
--------------

The peptide mixture was firstly separated by off-line reversed-phase liquid chromatography (RP-LC) at basic pH (pH = 10) to lower its complexity. The separation was performed on a HP 1200 system (Agilent Technologies, Santa Clara, CA, USA) employing a C18 reversed-phase column (Zorbax extend C18, 100 × 2.1 mm id, 3.5 μm, 300 Å; Agilent). The flow rate used was 0.2 mL/minute and the gradient was as in [Suppl. Fig. S2](#s1){ref-type="supplementary-material"}. The chromatogram was produced using a UV Detector at 214 nm. Several fractions were pooled post-collection (FC203B fraction collector, Gilson, Middleton, WI, USA) based on the peak intensity of the UV trace, yielding a total of 26 samples per LC run. Each fraction was dried in a vacuum concentrator and stored at −20°C for the next step of analysis. The dried peptide fractions were dissolved in 0.1% trifluoroacetic acid (TFA) and 2% acetonitrile; 5 μL of this sample were injected onto a capillary trap column (0.5 × 2 mm, Michrom Bioresources, Auburn, CA, USA) at a flow rate of 15 μl/minute. Peptides were desalted for 10 minutes and loaded onto a C18 column (Integrafit C18, Proteopep™ II, 75 μm id, 10.2 cm, 5 μm, 300 Å; New Objective, Woburn, MA, USA) at a constant flow rate of 350 nl/minute to perform the separation. Then peptides were separated using linearly increasing concentration of acetonitrile in buffer B. The RP analytical column eluent was spotted onto a matrix-assisted laser desorption/ionization (MALDI) sample plate using the Sun Collect MALDI Spotter/Micro Collector (SunChrom Wissenschaftliche Geräte GmbH, Germany) and analyzed by a 4800 mass spectrometer (AB Sciex). After the screening of all LC-MALDI sample positions in MS positive reflector mode, the fragmentation of automatically selected precursors was performed to generate fragment ions that provided sequence information for the peptide and reporter ions. MS and MS/MS parameters have been detailed elsewhere[@b20][@b26].

Data analysis
-------------

Protein identification and quantification were carried out using ProteinPilot™ software v.4.0 (ABSciex). Each MS/MS spectrum was searched in the Uniprot/Swissprot database (downloaded in May 2012) for *Homo sapiens*. Search parameters within ProteinPilot were set with trypsin cleavage specificity; methyl methanethiosulfate (MMTS) modified cysteine as fixed modifications; biological modification "ID focus" settings, and a protein minimum confidence score of 95%. Thus, the identity of the protein from the analyzed peptide was confirmed, and the ratios of the peak areas of iTRAQ reporter ions were used to compare the relative abundance of the protein identified in the sample. Only proteins identified with at least 95% confidence, or a Prot Score (protein confidence measure) of at least 1.3 were reported ([Supplementary Table S1](#s1){ref-type="supplementary-material"}). Data were normalized for loading error by bias and the background correction was calculated using the Pro Group™ algorithm (ABSciex). To determine the cutoff value for significant fold changes, coefficient of variation and cumulative frequency were calculated for the common proteins employing the R statistical package[@b58]. Using this tool, we considered statistically significant only those changes with a *p* value ≤ 0.05 and a ratio ≥ 1.4 (or ≤0.7). The results obtained from ProteinPilot were exported to Microsoft Excel for further analyses.

Real-time PCR assays
--------------------

Total RNA was isolated from OA and N HACs (5 × 10^5^ per well) using Trizol Reagent (Invitrogen), following the manufacturer\'s instructions. cDNA was synthesized from 1 μg total RNA, using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Basel, Switzerland) in accordance with the manufacturer\'s instructions, and analyzed by quantitative real-time PCR. Quantitative real-time PCR assay was performed in the LightCycler 480 instrument (Roche) using 96-well plates. Primers for THBS1, TGFBI and the housekeeping genes, HPRT1 and RPLP0, were designed using the Universal Probe Library tool from the Roche website (<http://www.roche-applied-science.com>). Primer sequences were as follows: THBS1 forward, 5′-GCTGCACTGAGTGTCACTGTC-3′; THBS1 reverse, 5′-TCAGGAACTGTGGCATTGG-3′; TGFBI forward, 5′- CGAGTGCTGTCCTGGATATG-3′; TGFBI reverse, 5′- CCCAGGGTCTCGTAAAGGTT-3′; HPRT1 forward, 5′-TGACCTTGATTTATTTTGCATACC-3′; HPRT1 reverse, 5′-CGAGCAAGACGTTCAGTCCT-3′; RPLP0 forward, 5′-TCTACAACCCTGAAGTGCTTGAT-3′, PRPL0 reverse 5′-CAATCTGCAGACAGACACTGG-3′. The results were analyzed using the LightCycler 480 software release 1.5.0 (Roche).

Western blot analysis
---------------------

Western blot analyses were performed utilizing standard procedures. Chondrocytes from 3 OA donors different from those selected for the proteomics strategy were used. Briefly, 20 μg of secreted proteins were loaded and resolved using 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were then transferred to polyvinylidene fluoride (PVDF) membranes (Immobilon P, Millipore Co., Bedford, MA, USA) by electro-blotting and probed with specific antibodies against THBS1 or TSP1 (Santa Cruz). Immunoreactive bands were detected by chemiluminescence using corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies and enhanced chemiluminescence (ECL) detection reagents (GE Healthcare), then digitized using the LAS 3000 image analyzer. Equivalent loadings were verified by Ponceau Red (Sigma) staining after transference (data not shown). Quantitative changes in band intensities were evaluated using ImageQuant 5.2 software (GE Healthcare).

Statistical analysis
--------------------

The statistical significance of the differences between mean values was determined using the two-tailed *t*-test, accepting p ≤ 0.05 to be significant. In the proteomic analysis, normalization tools and statistical package from ProteinPilot software were employed. Searches against a concatenated database containing both forward and reversed sequences allowed the false discovery rate (FDR) to be kept at 1%. Proteomics System Performance Evaluation Pipeline (PSPEP) software was used independently to calculate false discovery rates. Where appropriate, results are expressed as the mean ± standard error.
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![Protein-protein interaction network.\
The STRING database was searched for protein interaction analyses in order to elucidate the effect of CS alone and in combination with GlcN. As shown in this Figure, almost all (28) of the altered proteins interact with each other to constitute a big network. These proteins are involved in three main GO biological processes: (A) cell adhesion, (B) cartilage development, (C) and ECM organization.](srep05069-f2){#f2}

![Data mining.\
(A) Venn diagram depicting proteins modulated similarly and differently by CS-, GlcN- and CS + GlcN-treatment in OA HACs. Proteins in the green circle are modulated by CS, proteins in the violet circle are modulated by GlcN, and proteins in the blue circle are modulated by the combined treatment. All proteins are upregulated except VIM, MSN, HSP90AB1 and PKM2. (B) Component pie charts indicating the cellular localization of those proteins identified in the HACs secretome, according to Gene Ontology annotation.](srep05069-f3){#f3}

![Verification of the modulation of TGFBI and THBS1 in N*vs*OA HACs by Real-Time PCR.\
A significant increase (*p*value ≤ 0,05) in the gene expression of TGFBI (or BIGH3) and a decrease of THBS1 (or TSP1) were detected in OA (n = 7) HACs compared to normal (n = 6) cells. Results are expressed as the mean ± standard error.](srep05069-f4){#f4}

![Thrombospondin-1 (THBS1 or TSP1) is increased by CS alone and in combination with GH.\
Overexpression values of TSP1 were determined by real-time PCR (A) and Western blot analysis (B) of human articular chondrocytes from 3 OA donors. Results are expressed as mean ± SEM of 3 independent experiments. A representative image of Western blot is shown. \**p* \< 0.05: chondroitin sulfate (CS)-treated group was significantly different from unstimulated group (CTL) both at mRNA and protein level, while the combination of CS + GH (glucosamine hydrochloride) was effective only at protein level. ^&^*p* \< 0.05: GH-treated group was significantly different from CS + GH group at protein level.](srep05069-f5){#f5}

###### Secreted proteins identified by iTRAQ and LC-MS analysis as modulated by different treatments in OA HACs

  Score     \% Cov^95^   Accession[\#](#t1-fn1){ref-type="fn"}                                 Name                                  Symbol    Peptides    CS[\$](#t1-fn2){ref-type="fn"}    GlcN[\$](#t1-fn2){ref-type="fn"}   CS + GlcN[\$](#t1-fn2){ref-type="fn"}
  -------- ------------ --------------------------------------- ------------------------------------------------------------------ ---------- ---------- ---------------------------------- ---------------------------------- ---------------------------------------
  7,33         5,8                      Q9UHI8                   A disintegrin and metalloproteinase with thrombospondin motifs 1   ADAMTS1       5                     7,87                 1,44[\*](#t1-fn3){ref-type="fn"}                   7,18
  31,18        6,8                      P16112                                        Aggrecan core protein                           ACAN        18                    7,31                 2,88[\*](#t1-fn3){ref-type="fn"}                   9,29
  27,8         45,6                     P01011                                       Alpha-1-antichymotrypsin                       SERPINA3      18                    1,50                               1,47                                 1,54
  17,67        30,4                     P07355                                              Annexin A2                               ANXA2        10                    2,31                               2,38                                 2,13
  10,17        22,8                     P08758                                              Annexin A5                               ANXA5        6                     2,33                               2,70                   2,15[\*](#t1-fn3){ref-type="fn"}
  31,74        47,3                     P21810                                               Biglycan                                 BGN         38                    2,11                 1,26[\*](#t1-fn3){ref-type="fn"}                   2,25
  54,29        40,6                     P49747                                 Cartilage oligomeric matrix protein                    COMP        60      2,51[\*](#t1-fn3){ref-type="fn"}   1,89[\*](#t1-fn3){ref-type="fn"}                   3,25
  96,46        73,1                     P36222                                      Chitinase-3-like protein 1                       CHI3L1      236      3,38[\*](#t1-fn3){ref-type="fn"}                 3,19                                 4,33
  18,32        10,2                     Q76M96                               Coiled-coil domain-containing protein 80                CCDC80       9                     2,63                               1,61                                 2,40
  19,37        9,9                      P20908                                      Collagen alpha-1(V) chain                        COL5A1       17                    1,72                 1,17[\*](#t1-fn3){ref-type="fn"}                   1,96
  45,04        28,6                     P12109                                      Collagen alpha-1(VI) chain                       COL6A1       55                    2,68                 1,53[\*](#t1-fn3){ref-type="fn"}                   1,96
  158,4        35,9                     Q99715                                     Collagen alpha-1(XII) chain                      COL12A1      108                    5,50                               4,17                                 6,55
  129,14       68,2                     P08123                                      Collagen alpha-2(I) chain                        COL1A2      180                    2,15                 1,14[\*](#t1-fn3){ref-type="fn"}                   2,01
  80,88        16,9                     P12111                                      Collagen alpha-3(VI) chain                       COL6A3       49                    5,15                               2,70                                 3,91
  7,59         12,6                     P29279                                   Connective tissue growth factor                      CTGF        4                     2,54                 1,16[\*](#t1-fn3){ref-type="fn"}                   2,40
  13,63        21,8                     Q06828                                             Fibromodulin                               FMOD        11                    2,19                 1,47[\*](#t1-fn3){ref-type="fn"}                   1,71
  150,04       40,6                     P02751                                             Fibronectin                                FN1        147      0,86[\*](#t1-fn3){ref-type="fn"}   2,07[\*](#t1-fn3){ref-type="fn"}                   2,58
  55,85        64,3                     P07093                                          Glia-derived nexin                          SERPINE2      79                    6,98                               2,44                                 7,87
  5,12         4,1                      P08238                                    Heat shock protein HSP 90-beta                     HSP90B       3                     0,28                 0,54[\*](#t1-fn3){ref-type="fn"}     0,50[\*](#t1-fn3){ref-type="fn"}
  19,69        35,6                     P10915                              Hyaluronan and proteoglycan link protein 1               HAPLN1       14                    4,70                 1,44[\*](#t1-fn3){ref-type="fn"}                   4,88
  18,38        25,6                     P00338                                   L-lactate dehydrogenase A chain                      LDHA        13      1,54[\*](#t1-fn3){ref-type="fn"}                 1,89                   1,67[\*](#t1-fn3){ref-type="fn"}
  43,27        43,5                     P51884                                               Lumican                                  LUM        100      2,29[\*](#t1-fn3){ref-type="fn"}   1,56[\*](#t1-fn3){ref-type="fn"}                   1,91
  16,35        30,9                     P20774                                               Mimecan                                  OGN         15                    1,92                 1,05[\*](#t1-fn3){ref-type="fn"}     1,47[\*](#t1-fn3){ref-type="fn"}
  15,89         13                      P26038                                                Moesin                                  MSN         10                    0,52                 1,14[\*](#t1-fn3){ref-type="fn"}     0,95[\*](#t1-fn3){ref-type="fn"}
  7,86         13,4                     P26022                                    Pentraxin-related protein PTX3                      PTX3        7                     3,77                 2,65[\*](#t1-fn3){ref-type="fn"}                   4,06
  19,36         20                      P05155                                     Plasma protease C1 inhibitor                     SERPING1      12                    1,63                 1,39[\*](#t1-fn3){ref-type="fn"}                   1,64
  15,15        25,2                     Q15113                                Procollagen C-endopeptidase enhancer 1                 PCOLCE       10                    1,82                 1,29[\*](#t1-fn3){ref-type="fn"}     1,82[\*](#t1-fn3){ref-type="fn"}
  13,57        35,2                     P01210                                           Proenkephalin-A                              PENK        8       1,39[\*](#t1-fn3){ref-type="fn"}                 1,49                                 1,54
  23,69        26,4                     P14618                                    Pyruvate kinase isozymes M1/M2                      PKM2        12                    0,53                 0,89[\*](#t1-fn3){ref-type="fn"}                   0,63
  26,09        33,5                     P08254                                            Stromelysin-1                               MMP3        19                    1,82                               1,41                                 1,54
  22,05        11,3                     Q7Z7G0                                          Target of Nesh-SH3                           ABI3BP       11                    2,03                 1,19[\*](#t1-fn3){ref-type="fn"}                   2,56
  88,43         28                      P24821                                               Tenascin                                 TNC         61                    3,60                               2,44                                 3,66
  19,55         12                      P07996                                           Thrombospondin-1                            THBS1        15                    4,09                 1,03[\*](#t1-fn3){ref-type="fn"}                   3,37
  59,59        57,4                     Q15582                        Transforming growth factor-beta-induced protein ig-h3          TGFBI        63                    2,58                 1,82[\*](#t1-fn3){ref-type="fn"}     1,20[\*](#t1-fn3){ref-type="fn"}
  15,2         17,5                     P19320                                   Vascular cell adhesion protein 1                    VCAM1        11                    3,10                 1,14[\*](#t1-fn3){ref-type="fn"}                   2,83
  51,29        53,7                     P08670                                               Vimentin                                 VIM         40                    0,68                 1,57[\*](#t1-fn3){ref-type="fn"}     1,02[\*](#t1-fn3){ref-type="fn"}

^\#^Protein accession number according to SwissProt and TrEMBL databases.

^\$^Average iTRAQ ratios that represent the relative protein abundance in treated (CS, chondroitin sulfate; GlcN, glucosamine hydrochloride) *vs* untreated cells, calculated by Protein Pilot 3.0 software. A *p*-value ≤ 0.05 was accepted.

\*Not statistically significant change.

###### In table 2A the average iTRAQ ratios represent the relative protein abundance in cells treated with the combined formulation *vs* glucosamine (GlcN)-treated cells. In table 2B, the ratios represent the effect of the combined formulation vs chondroitin sulfate (CS) alone

  A\)                                                                                               
  -------- ------------------------------------------------------------------ ---------- ------ -------
  Q9UHI8    A disintegrin and metalloproteinase with thrombospondin motifs 1   ADAMTS1    5,50   0,038
  P16112                         Aggrecan core protein                           ACAN     3,37   0,000
  P21810                                Biglycan                                 BGN      1,80   0,003
  P49747                  Cartilage oligomeric matrix protein                    COMP     1,74   0,035
  Q76M96                Coiled-coil domain-containing protein 80                CCDC80    1,47   0,023
  P02452                       Collagen alpha-1(I) chain                        COL1A1    1,51   0,055
  P02461                      Collagen alpha-1(III) chain                       COL3A1    1,71   0,056
  P20908                       Collagen alpha-1(V) chain                        COL5A1    1,66   0,020
  Q99715                      Collagen alpha-1(XII) chain                      COL12A1    1,63   0,001
  P08123                       Collagen alpha-2(I) chain                        COL1A2    1,75   0,008
  P12111                       Collagen alpha-3(VI) chain                       COL6A3    1,45   0,026
  P07093                           Glia-derived nexin                          SERPINE2   3,44   0,000
  P10915               Hyaluronan and proteoglycan link protein 1               HAPLN1    3,63   0,003
  Q99985                             Semaphorin-3C                              SEMA3C    3,50   0,019
  Q7Z7G0                           Target of Nesh-SH3                           ABI3BP    2,17   0,001
  P24821                                Tenascin                                 TNC      1,50   0,000
  P07996                            Thrombospondin-1                            THBS1     3,28   0,000
  P19320                    Vascular cell adhesion protein 1                    VCAM1     2,56   0,009
  P08670                                Vimentin                                 VIM      0,63   0,001

  B\)                                                                                 
  -------- ------------------------------------------------------- ------- ------ -------
  P02751                         Fibronectin                         FN1    2,94   0,000
  Q15582    Transforming growth factor-beta-induced protein ig-h3   TGFBI   0,45   0,015
  P08670                          Vimentin                           VIM    1,46   0,002
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\#Protein accession number according to SwissProt and TrEMBL databases.

\#Protein accession number according to SwissProt and TrEMBL databases.

###### Pharmacoproteomic studies carried out on normal (N) and osteoarthritic (OA) human articular chondrocytes (HACs) treated with different types of chondroitin sulfate compounds (bCS: bovine CS; pCS: porcine CS) and formulations (CS alone and combined with glucosamine sulfate, GS, or glucosamine hydrochloride, GH). Different proteomics approaches were employed both gel-based (2DE: two dimensional gel electrophoresis; DIGE: difference gel electrophoresis; and SILAC: stable isotope labeling with amino acids in cell culture) and gel-free techniques (iTRAQ: isobaric tags for relative and absolute quantitation). Novel molecular target for OA treatment were identified in such studies: 78 kDa glucose-regulated protein precursor (GRP78); superoxide dismutase \[Mn\], mitochondrial (SOD2); pyruvate kinase isozymes M1/M2 (PKM2); fructose-bisphosphate aldolase A (ALDOA); triosephosphate isomerase (TPIS); vimentin (VIM); thrombospondin-1 (THBS1); tumor necrosis factor-inducible gene 6 protein (TSG6); interstitial collagenase (MMP1); stromelysin-1 (MMP3); aggrecan core protein (ACAN); hyaluronan and proteoglycan link protein 1 (HAPLN1); transforming growth factor-beta-induced protein ig-h3 (TGFBI)

  Reference                   Technique          Sample           Cell type                      Treatment                                                         Results                                               New targets
  -------------------------- ------------ -------------------- ---------------- -------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------
  Calamia *et al* \[2010\]       2DE            Proteome        N HACs (+IL1β)               bCS, GS, bCS + GS                              different intracellular pathways affected by CS or GS                 GRP78/SOD2/PKM2/ALDOA/TPIS
  Calamia *et al* \[2012\]    DIGE/SILAC   Proteome/Secretome      OA HACs       bCS (96%/100% purity) and pCS (90% purity)   variable effects of 3 different CS compounds dependent on their origin and purity         SOD2/MMP1/VIM
  Calamia *et al* \[2012\]      SILAC          Secretome        N HACs (+IL1β)                      bCS                       evidences of CS anti-angiogenic, anti-inflammatory, and anti-catabolic properties      THBS1/TSG6/MMP1/MMP3
  Calamia *et al* \[2013\]      iTRAQ          Secretome           OA HACs                   bCS, GH, bCS + GH                                     synergistic effect in 33% of the cases                          ACAN/HAPLN1/THBS1/TGFBI
